Sumitomo Chemical Company, Limited
Stock Price Chart
2026/08/13 UpdatedPrice Trend
2026/08/13 UpdatedPrice & Trading Details
2026/08/13 UpdatedPRICE
TRADING
Analyst Recommendations 10 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/14 | ¥-18.94 | ¥-16.22 | +14.4% |
| 2026/02/02 | ¥-1.73 | ¥29.12 | +1,778.6% |
| 2025/11/03 | ¥15.29 | ¥27.02 | +76.7% |
| 2025/08/01 | ¥-0.73 | ¥-2.76 | -276.1% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
22.0M | +0.04% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
14.5M | +3.60% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
10.6M | 0.00% | |
|
BlackRock Funds-BlackRock Advantage International Fund
|
7.2M | -24.88% | |
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
6.6M | +9.06% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
5.9M | +0.22% |
Dividend History
Updated 2026/08/09| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥8 | -37.5% |
| 2025 | ¥12 | +100.0% |
| 2024 | ¥6 | -50.0% |
| 2023 | ¥12 | -53.8% |
| 2022 | ¥26 | - |
Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,765,321M | ¥2,895,283M | ¥2,446,893M | ¥2,606,281M |
| Gross Profit | ¥873,863M | ¥820,926M | ¥499,695M | ¥725,476M |
| Operating Income | ¥172,823M | -¥24,187M | -¥431,428M | ¥172,394M |
| Pretax Income | ¥274,197M | ¥39,852M | -¥415,829M | ¥210,683M |
| Net Income | ¥162,130M | ¥6,987M | -¥311,838M | ¥38,591M |
| EPS | ¥99.16 | ¥4.27 | -¥190.69 | ¥23.58 |
| Operating Margin | 6.25% | -0.84% | -17.63% | 6.61% |
| Balance Sheet | ||||
| Total Assets | ¥4,308,151M | ¥4,165,503M | ¥3,934,818M | ¥3,439,784M |
| Total Equity | ¥1,218,101M | ¥1,171,192M | ¥965,753M | ¥900,790M |
| Total Liabilities | ¥3,090,050M | ¥2,994,311M | ¥2,969,065M | ¥2,538,994M |
| Cash | ¥365,429M | ¥305,844M | ¥217,449M | ¥209,838M |
| Interest-bearing Debt | ¥1,350,470M | ¥1,461,366M | ¥1,563,486M | ¥1,286,128M |
| Equity Ratio | 28.27% | 28.12% | 24.54% | 26.19% |
| D/E Ratio | 1.11 | 1.25 | 1.62 | 1.43 |
| Cash Flow | ||||
| Operating CF | ¥171,715M | ¥111,621M | -¥51,317M | - |
| Investing CF | -¥115,421M | -¥19,411M | -¥112,240M | - |
| Financing CF | -¥81,394M | -¥178,502M | ¥49,246M | - |
| Free CF | ¥171,715M | -¥31,960M | -¥204,190M | - |
| Efficiency | ||||
| ROE | 13.31% | 0.60% | -32.29% | 4.28% |
| ROA | 3.76% | 0.17% | -7.93% | 1.12% |
Latest IR Information
-
About this report (Sumitomo Chemical and Sumitomo Pharmaceutical: Part II – CiRA, Dr. Yamanaka, and the undisclosed history of image-duplication concerns)
Notice regarding the Sumitomo Group report. Explains GCR's view and related stock matters, and the reliability of AmScheprei's approved materials. Contents include product and research review, legal responses, and outlines future actions.
Read more -
About Our Group Report (Additional Explanation Regarding "Sumitomo Chemical and Sumitomo Pharmaceutical: The ¥116 Billion Swiss Shuffle")
Publication of additional explanations on the GCR report. Clarifies the breakdown of consolidated results for the fiscal year ending March 2026, background of accounts receivable increases, and dividend treatment in individual financial statements, correcting points of discrepancy with facts.
Read more -
Sumitomo Chemical Company, Limited: FY2027 Q1 IFRS Consolidated Financial Results (Quarterly) (Unaudited)
IFRS consolidated results for the first quarter of the fiscal year ending March 2027 were disclosed. Highlights include revenue, operating income, and net income, with year-over-year and quarter-on-quarter comparisons. Segment performance, financial position, cash flows, and quarterly net income are...
Read more -
Notice regarding the confirmation of the amount of capital surplus decreasing due to the stock swap and the transfer to primary capital surplus
The decrease in capital surplus due to the stock swap is 2,399,926,534 yen, with the transfer to other capital surplus confirmed. The decrease is calculated based on the market value of the shares issued as consideration for the stock swap,...
Read more -
Notice of Effective Date of Business Integration Agreements for Sumitomo Chemical Co., Ltd.
As of today, Sumitomo Chemical announces the effective date of the agreements related to the integration of the domestic polyolefin business. The structure involves a two-stage plan including an absorption-type company split, with Prime Polymer acquiring the business and Sumitomo...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥663
Rating Score: 2.00 (Based on 10 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Sumitomo Chemical Company, Limited engages in Agro & Life Solutions, ICT & Mobility Solutions, Advanced Medical Solutions, Essential & Green Materials, and Sumitomo Pharma. The Agro & Life Solutions segment offers crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, and feed additives, etc. The ICT & Mobility Solutions segment provides optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, high-purity aluminum and alumina, specialty chemicals, additives, engineering plastics, and battery materials, etc. The Advanced Medical Solutions segment offers contract development and manufacturing organization business for small-molecule active ingredients and intermediates, oligonucleic acid drug substances, and regenerative medicine, and cell therapy products, etc. The Essential & Green Materials segment offers synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, industrial aluminum and alumina, and synthetic rubber, etc. The Sumitomo Pharma segment offers small molecule pharmaceuticals. Additionally, the company engages in the manufacture and sale of positive electrode materials for rechargeable batteries. Sumitomo Chemical Company, Limited was founded in 1913 and is headquartered in Tokyo, Japan.
